Background-Studies suggest that treatment-resistant hypertension is common and increasing in prevalence among US adults. While hypertension is a risk factor for end-stage renal disease (ESRD), few data are available on the association between treatment-resistant hypertension and ESRD risk.
Financial Disclosure: The authors declare that they have no other relevant financial interests. Table S1 : Number of antihypertensive medication classes being taken and percent of participants taking each class. Table S2 : Sensitivity analyses for ESRD associated with treatment-resistant HTN. Table S3 : Characteristics of participants without treatment-resistant HTN and with controlled vs uncontrolled treatment-resistant HTN. Table S4 : HRs for incident ESRD associated with uncontrolled BP in participants with treatment-resistant HTN. Note: The supplementary material accompanying this article (doi: ________ ) is available at www.ajkd.org Treatment-resistant hypertension is defined as uncontrolled blood pressure (BP) with concurrent use of 3 or more antihypertensive medication classes, or as use of 4 or more antihypertensive medication classes regardless of BP level. Ideally, one of these antihypertensive medication classes should be a diuretic and every agent should be prescribed at an optimal dosage. 1 Based on data from the 2005-2008 National Health and Nutrition Examination Surveys (NHANES), Egan, et al. estimated the prevalence of treatment-resistant hypertension to be 11.8% among hypertensive adults. 2 End-stage renal disease (ESRD) is associated with a heavy economic burden and excess risk of mortality. 3 Hypertension affects the majority of individuals with chronic kidney disease (CKD) and is a major risk factor for ESRD. [4] [5] [6] Further, recent studies have reported a high prevalence of treatment-resistant hypertension among individuals with CKD. [7] [8] [9] Treatmentresistant hypertension has been associated with increased risk of coronary heart disease, stroke, all-cause mortality and, in small clinic-based samples, ESRD. 9, 10 However, few data are available on ESRD risk in a large, population-based sample of persons with treatmentresistant hypertension. The goal of the current analysis was to determine whether individuals with treatment-resistant hypertension have an increased risk for ESRD. To do so, we analyzed data from adults participating in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study.
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Methods
Study Participants
The REGARDS Study enrolled a population-based sample of black and white US adults aged 45 years or older. 11 Between June 2003 and October 2007, 30,239 individuals were enrolled from the 48 contiguous US states and the District of Columbia. 11 Participants with hypertension who were taking ≥ 1 class of antihypertensive medication and did not have prevalent ESRD at baseline (n=14,734) formed the base population for the present analysis. Prevalent ESRD was defined by self-report of receipt of dialysis or an ESRD incidence date in the US Renal Data System (USRDS) prior to the REGARDS in-home visit date. Those missing BP, serum creatinine, or albumin-creatinine ratio (ACR) data or information on medications they were taking (n=1,295) were excluded from all analyses. We also excluded participants with uncontrolled BP taking 1 or 2 antihypertensive medication classes (n=3,465) from the main analyses, as we were unable to determine whether these participants had treatment-resistant hypertension. As described below, these participants were included in sensitivity analyses. After these exclusion criteria were applied, data from 9,974 hypertensive participants were included in the main analyses. The REGARDS Study protocol was approved by the institutional review boards governing research in human subjects at the participating centers and all participants provided written consent.
Data Collection
Baseline REGARDS Study data were collected through a computer-assisted telephone interview, an in-home examination conducted in the morning, and self-administered questionnaires. Of relevance to the current analysis, information on the following demographic, behavioral and medical history characteristics was collected during the telephone interview: age, sex, race, region of residence, education, annual household income, smoking status, alcohol consumption, frequency of physical activity, and a history of diabetes, stroke, or myocardial infarction (MI). Medication adherence was assessed using the 4-item Morisky Medication Adherence Scale.
During the in-home examination, two BP measurements were made by trained personnel using standardized protocols. Also, an electrocardiogram was obtained, waist circumference was measured, and blood and urine samples were collected and sent to a central laboratory for analysis. A pill bottle review was conducted to record the names of all prescription and over-the-counter medications participants reported taking during the 2 weeks preceding the in-home study visit. Total and high-density lipoprotein (HDL) cholesterol were measured by colorimetric reflectance spectrophotometry and high sensitivity C-reactive protein was measured using a high-sensitivity particle-enhanced immunonephelometric assay. Serum glucose was measured by colorimetric reflectance spectrophotometry on the Ortho Vitros 950 IRC Clinical Analyzer (Johnson & Johnson Clinical Diagnostics), and diabetes was defined as a fasting serum glucose level ≥ 126 mg/dL, non-fasting serum glucose level ≥ 200 mg/dL, or use of antidiabetes medication. Serum creatinine was measured using an isotope-dilution mass spectrometry (IDMS)-traceable method. Estimated glomerular filtration rate (eGFR) was calculated via the CKD-EPI (CKD Epidemiology Collaboration) creatinine equation 12 and categorized as ≥ 60, 45-59, or < 45 mL/min/1.73 m 2 . Urinary albumin was measured with the BN ProSpec Nephelometer (Dade Behring, Marburg, Germany) and urinary creatinine was measured with a rate-blanked Jaffé procedure, using the Modular-P analyzer (Roche/Hitachi; Indianapolis, IN). The ACR was categorized as < 30 or ≥ 30 mg/g.
Definition of Treatment-Resistant Hypertension
During the in-home examination, BP was measured twice by trained technicians following a standardized protocol using aneroid sphygmomanometers. Participants were asked to sit quietly for 5 minutes with both feet on the floor prior to the BP measurements. Measurements were taken using an appropriately sized cuff, which was inflated to 20 mmHg above the pulse obliteration level and slowly deflated. After a 30-second rest period, this process was repeated on the same arm to obtain the second BP measurement. 13 Quality control for BP measurement in the REGARDS Study was monitored by central examination of digit preference and technicians were retrained as necessary. 11 The two BP measurements were averaged for analysis. Uncontrolled BP was defined as systolic BP ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg except for individuals with an ACR ≥ 30 mg/g wherein uncontrolled BP was defined as systolic BP ≥ 130 mmHg and/or diastolic BP ≥ 80 mmHg. 14 Medication names recorded during the pill bottle review were coded into generic drug names and subsequently grouped into drug classes. One-pill combinations were classified into multiple medication classes. Each generic drug name was counted in only one class. Drug dose was not recorded. Antihypertensive medication classes were defined using the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC-7). 15 For the purposes of this study, treatmentresistant hypertension was defined as uncontrolled BP with concurrent use of 3 antihypertensive medication classes including a diuretic or as use of ≥ 4 antihypertensive medication classes including a diuretic regardless of BP level. In the main analyses, the comparison group (i.e. "no treatment-resistant hypertension") was comprised of participants with controlled BP on 3 or fewer classes of antihypertensive medication. In sensitivity analyses, the comparison group also included participants with uncontrolled BP on 1 or 2 classes of antihypertensive medication.
Definition of ESRD
Incident cases of ESRD were identified through linkage of REGARDS Study participants with the USRDS, which records virtually all incident ESRD cases in the United States. A finder file with unique individual identifiers (name, social security number, and date of birth) was submitted for linkage with the USRDS. Different configurations of full and partial individual identifiers were then sequentially matched. For participants with a partial match to the USRDS, the nonmatching variables were visually inspected to confirm a valid match could not be made. Data from the USRDS included all incident ESRD cases, regardless of treatment modality, through September 30, 2011. For participants not developing ESRD, follow up time ended on their date of death (ascertained through death certificates, National Death Index data, or Social Security Death Index) or, for those who remained alive, September 30, 2011.
Statistical Analysis
Baseline characteristics of REGARDS participants were calculated by treatment-resistant hypertension status. The cumulative incidence of ESRD was calculated using the Kaplan-Meier method for participants with and without treatment-resistant hypertension. Next, using Cox proportional hazards regression models, the crude (unadjusted); age, race-, sexadjusted; and multivariable-adjusted hazard ratios (HRs) for ESRD associated with treatment-resistant hypertension were calculated for the overall population and for subgroups defined by age, race, sex, history of diabetes, MI, and stroke. Multivariable adjustment included age, race, sex, region of residence, education, income, physical activity, current smoking, alcohol use, statin use, waist circumference, diabetes, total cholesterol, high-density lipoprotein cholesterol, C-reactive protein, and history of MI and stroke.
We did not adjust for ACR or eGFR in the main analyses, since they may be in the causal pathway between treatment-resistant hypertension and ESRD. [16] [17] [18] Instead, we calculated multivariable adjusted HRs for ESRD associated with treatment-resistant hypertension stratified by level of baseline ACR (< 30 or ≥ 30 mg/g) and baseline eGFR (≥ 60, 45-59, and <45 mL/min/1.73 m 2 ). To reduce model over-fitting in these stratified analyses, we calculated each participant's propensity (i.e. predicted probability) for having treatmentresistant hypertension based on variables in the multivariable adjusted model described above. We then adjusted for this propensity in the regression model rather than adjusting for each covariate individually. In sensitivity analyses, we calculated the incidence rates and HRs for ESRD associated with treatment-resistant hypertension (1) limited to participants with perfect medication adherence, defined by appropriate medication-taking behaviors on all 4 Morisky Medication Adherence Scale items, (2) including the 3,465 participants with uncontrolled BP on 1 or 2 classes of antihypertensive medication in the analysis and categorizing this group as not having treatment-resistant hypertension, and (3) including adjustment for ACR and eGFR in a final multivariable model. Also, we calculated incidence rates and HRs for ESRD comparing participants with treatment-resistant hypertension and controlled BP and, separately, with uncontrolled BP to participants without treatmentresistant hypertension. The HRs for ESRD were also calculated for those with treatmentresistant hypertension comparing participants with uncontrolled versus controlled BP. All analyses were conducted using SAS version 9.2 (SAS Institute Inc, Cary, NC).
Results
Participant Characteristics
After excluding participants with uncontrolled BP on 1 or 2 classes of antihypertensive medication, 21.5% of REGARDS Study participants with hypertension had treatmentresistant hypertension. Participants with treatment-resistant hypertension were older on average than their counterparts without treatment-resistant hypertension and more likely to be black, have an annual household income <$20,000, have less than a high school education, use statins, and have diabetes or a history of MI or stroke (Table 1) . Those with treatment-resistant hypertension were less likely to be female, to consume alcohol or to participate in physical activity. On average, participants with treatment-resistant hypertension had a larger waist circumference, higher systolic and diastolic BPs and ACR, and lower total cholesterol, HDL cholesterol, and eGFR than those without treatmentresistant hypertension. Details on the number and classes of antihypertensive medications being taken by participants with and without treatment-resistant hypertension are provided in Table S1 (provided as online supplementary material).
Treatment-Resistant Hypertension and Incident ESRD
Over a median follow-up of 6.4 (maximum, 8.6) years, 152 participants developed ESRD. Of the 152 cases of incident ESRD, 110 (72%) had treatment-resistant hypertension at the baseline study visit. The cumulative incidence of ESRD was higher for participants with versus without treatment-resistant hypertension (Figure 1 ). The incidence of ESRD was 8.86 (95% confidence interval [CI], 7.35-10.68) and 0.88 (95% CI, 0.65-1.19) per 1,000 personyears among participants with and without treatment-resistant hypertension, respectively ( Table 2 ). This association was present after age, race, sex and multivariable adjustment and in sub-groups defined by age, race, gender, and a history of diabetes, MI, or stroke ( Figure  2) . Results were similar when analyses were limited to participants with perfect medication adherence and when participants with uncontrolled BP on 1 or 2 classes of antihypertensive medication were included in the analysis as not having treatment-resistant hypertension; however, treatment-resistant hypertension was not associated with ESRD after multivariable adjustment including ACR and eGFR (HR, 1.39; 95% CI, 0.92-2.11; Table S2 ).
For both participants with and without treatment-resistant hypertension, ESRD incidence increased as level of ACR increased and eGFR decreased (Table 3) . Additionally, within each ACR and eGFR category, the crude ESRD incidence rate was higher among participants with versus without treatment-resistant hypertension. The propensity-adjusted HRs for ESRD associated with treatment-resistant hypertension among those with ACR levels < 30 and ≥ 30 mg/g were 1.55 (95% CI, 0.61-3.94) and 2.54 (95% CI, 1.61-4.00), respectively. The propensity-adjusted HRs for ESRD comparing participants with and without treatment-resistant hypertension were 3.57 (95% CI, 1.58-8.07), 6.53 (95% CI, 1.86-22.96), and 3.22 (95% CI, 2.01-5.15) for participants with eGFR ≥60, 45-59, and <45 mL/min/1.73 m 2 , respectively.
ESRD Associated With Controlled and Uncontrolled BP
Characteristics of the study population with treatment-resistant hypertension by BP control are shown in Table S3 . Participants with treatment-resistant hypertension and controlled BP and treatment-resistant hypertension with uncontrolled BP each had a higher risk of ESRD when compared to participants without treatment-resistant hypertension ( Table 4 ). After multivariable adjustment and compared to those without treatment-resistant hypertension, the HRs for ESRD were 2.89 (95% CI, 1.52-5.47) and 7.68 (95% CI, 5.18-11.40) for those with treatment-resistant hypertension and controlled and uncontrolled BP, respectively. After multivariable adjustment and compared to those with treatment-resistant hypertension and controlled BP, the HR for ESRD was 2.69 (95% CI, 1.49-4.86) for participants with treatment-resistant hypertension and uncontrolled BP (Table S4 ).
Discussion
Using data from a large, population-based sample of black and white adults, we found a strong association between treatment-resistant hypertension and incident ESRD, which persisted after multivariable adjustment. The incidence rate of ESRD among people with treatment-resistant hypertension in this population-based study (8.86 per 1,000 person-years) is over two times higher than USRDS estimates for blacks with diabetes (4.0 per 1,000 population), a population which has historically been considered at especially high risk of ESRD. 3 In addition, although 22% of REGARDS participants had treatment-resistant hypertension at baseline, 72% of those who went on to develop ESRD during follow-up had treatment-resistant hypertension at their baseline study visit. These data suggest that treatment-resistant hypertension might be an important marker for increased ESRD risk.
The association between treatment-resistant hypertension and ESRD has been examined in clinic-based studies. 7, 9 De Nicola and colleagues reported treatment-resistant hypertension to be associated with increased risk of the composite outcome of dialysis, transplantation, or death over a median of 37.6 months of follow-up (HR, 1.85; 95% CI, 1.13-3.03) among 300 patients with CKD. 7 More recently, the same group reported an increased risk for cardiovascular events and renal events among 436 clinic patients with treatment-resistant hypertension over 57 months of follow-up (HRs of 1.98 [95% CI, 1.14-3.43] and 2.66 [95% CI, 1.62-4.37], respectively). 9 Also, in a study of individuals enrolled in the international Reduction of Atherothrombosis for Continued Health (REACH) registry, treatment-resistant hypertension versus no treatment-resistant hypertension was associated with a multivariable adjusted HR of 1.11 (95% CI, 1.02-1.20) for the composite outcome of cardiovascular death, MI, or stroke. 19 In the current study, treatment-resistant hypertension, regardless of BP control, was associated with an increased risk for ESRD. Furthermore, treatment-resistant hypertension with uncontrolled BP was associated with an increased risk for ESRD compared to treatment-resistant hypertension with controlled BP, suggesting that, among individuals with CKD, prevention of treatment-resistant hypertension and achieving BP control among those with treatment-resistant hypertension are important. Achieving BP control is a key challenge in the management of individuals with CKD; 20 however, prior studies suggest that, with appropriate interventions, BP control can be achieved and maintained even in populations in which BP control is difficult. [21] [22] [23] [24] In addition, randomized controlled trials have demonstrated that, among individuals with treatment-resistant hypertension, catheter-based renal denervation can reduce BP in individuals without major adverse effects or changes in kidney function. 25, 26 However, the optimal BP goal for reducing cardiovascular disease and improving kidney disease outcomes is unclear and whether renal denervation slows the progression of CKD is not known. A small randomized trial demonstrated that reductions in dietary sodium are associated with lower BP among individuals with treatment-resistant hypertension. 27 Data from randomized trials are needed to assess the benefits of reducing dietary sodium intake on cardiovascular outcomes among individuals with treatmentresistant hypertension.
The findings of the current study emphasize the need for appropriate clinical management strategies to lower BP among individuals with treatment-resistant hypertension. The American Heart Association scientific statement on diagnosis, evaluation, and treatment of treatment-resistant hypertension recommends diuretics as first-line therapy for persons with hypertension, with the subsequent addition of an ACE inhibitor or angiotensin receptor blocker (ARB) and then a calcium channel blocker, as needed to achieve BP control. 1 Furthermore, among individuals with treatment-resistant hypertension, clinical trials indicate that the addition of an aldosterone antagonist lowers systolic BP by 20-25 mm Hg and diastolic BP by 10-15 mm Hg. 28, 29 However, in the current study, less than 10% of individuals with treatment-resistant hypertension were taking an aldosterone antagonist. Ineffective antihypertensive therapy, including sub-optimal drug combination strategies, constitutes a barrier to BP control. Comparative effectiveness studies are needed to test the effects of different multi-drug medication regimens on BP, cardiovascular and kidney disease outcomes in individuals with treatment-resistant hypertension.
Our study minimizes misclassification of the treatment-resistant hypertension phenotype through the use of a pill-bottle review to identify the number of antihypertensive medication classes being taken, standardized in-home BP measurement, and assessment of medication adherence. Other strengths include the large, population-based sample of blacks and whites and the availability of linkage with the USRDS, which captures virtually all incident ESRD cases in the United States. However, the findings of the current study should be considered in the context of certain limitations. Albuminuria, BP, and eGFR were assessed at a single time point, making misclassification of CKD and treatment-resistant hypertension status possible. An additional limitation is the lack of medication dosing information. Some individuals may have been on an inadequate treatment regimen and thus were not truly treatment-resistant. Ambulatory BP monitoring was not available to rule out white-coat hypertension. Also, we do not have data on potential secondary causes of treatment-resistant hypertension or genetic data to investigate the potential contribution of disease-promoting haplotypes. In the current study, the association between treatment-resistant hypertension and ESRD was attenuated by adjustment for ACR and reduced eGFR, suggesting that these are either confounders or mediators between treatment-resistant hypertension and ESRD risk. Given the strong association between hypertension, reduced eGFR, and albuminuria, it is possible that albuminuria and reduced eGFR might be in the causal pathway between treatment-resistant hypertension and ESRD risk. 30 However, with the data currently available in the REGARDS Study, we cannot rule out the possibility that they are confounders.
In conclusion, data from the current study demonstrate an increased risk for ESRD among individuals with treatment-resistant hypertension. Additionally, a substantial proportion of participants who developed ESRD had treatment-resistant hypertension at baseline. Strategies are needed to prevent and treat treatment-resistant hypertension in an effort to reduce the incidence of ESRD.
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